tonsoku like, DNA repair proteinGenealiases: IKBR · NFKBIL2 · SEMDSP
Q-omics provides the consensus-scored TONSL profile across patient tissues and cancer cell-line models. TONSL expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TONSL is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TONSL protein abundance shows 22,463 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where TONSL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TONSL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TONSL survival associations across molecular data types. TONSL RNA expression shows survival associations in the most cancer types (29), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TONSL RNA expression–survival associations across cancer types. High TONSL expression shows unfavorable associations in ACC, MESO, LIHC, KIRC, THCA and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TONSL RNA expression.
This table summarizes TONSL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TONSL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TONSL shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, BLCA, KIRP and STAD. The HNSC box plot shows higher TONSL RNA expression in tumor versus normal tissue (log2 FC = +1.814, t-test p < 0.001).
This table shows molecular features associated with TONSL in patient tissues and cancer cell lines. In patient samples, TONSL shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TONSL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
